Trial Profile
A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2020
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EXTRA
- Sponsors Novo Nordisk
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 11 Dec 2017 According to a Novo Nordisk media release, data from the study has been published the peer-reviewed journal Diabetes, Obesity and Metabolism.
- 11 Dec 2017 Results published in a Novo Nordisk media release.